The FDA has greenlighted the application from BioXcel Therapeutics to begin a clinical trial on its agitation drug for patients with delirium.
This would be the fifth potential disease indication BioXcel is eyeing for BXCL501, which dissolves in the mouth and is similar to a mouthwash strip.